- Investor's Business Daily•13 hours ago
Leerink Swann analyst Geoffrey Porges is "tired of waiting" for Gilead Sciences to acknowledge slowing hepatitis C patient volume and competition from rivals AbbVie and Merck.
- Business Wire•13 hours agoGilead Sciences and the World Health Organization Announce Five-Year Visceral Leishmaniasis Collaboration
Gilead Sciences, Inc. today announced it has entered into a partnership with the World Health Organization to provide $20 million in funding and drug donations over five years to expand access to diagnostic services and treatment for visceral leishmaniasis .
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||79.20 x 200|
|Ask||79.70 x 100|
|Day's Range||78.64 - 79.88|
|52wk Range||76.67 - 111.11|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||6.96|
|Avg Vol (3m)||10,650,853|
|Dividend & Yield||1.88 (2.33%)|